SHARP-2 gene silencing by lentiviral-based short hairpin RNA interference prolonged rat kidney transplant recipients' survival time

Journal of International Medical Research

Volumn 37, Issue 3, 2009, Pages 766-778

  Shou, Zhangfei ^a,b   Xiao, H ^b   Xu, Y ^b   Wang, Y ^c   Yang, Y ^a   Jiang, H ^b   Chen, J ^a,b   Yamada, K ^d,e   Miyamoto, K ^d  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c SHIHEZI UNIVERSITY   (China)

^d UNIVERSITY OF FUKUI   (Japan)

^e MATSUMOTO UNIVERSITY   (Japan)

Author keywords

Gene silencing; Interferon ; Interleukin 2; Lentivirus; Rat kidney transplantation; RNA interference; Sharp 2 gene expression; Short hairpin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; SPLIT AND HAIRY RELATED PROTEIN 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BHLHB2 PROTEIN, RAT; GREEN FLUORESCENT PROTEIN; HOMEODOMAIN PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE CONSTRUCT; GENE EXPRESSION; GENE SILENCING; GRAFT RECIPIENT; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; METABOLISM; RNA INTERFERENCE; T LYMPHOCYTE; TIME;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; LENTIVIRUS; LYMPHOCYTE ACTIVATION; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TIME FACTORS;

EID: 70349234003     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700320     Document Type: Article

References (23)

1. Galliford J, Game DS: Modern renal transplantation: present challenges and future prospects. Postgrad Med J 2009; 85: 91-101.
2. Karczewski J, Karczewski M, Glyda M, et al: Role of TH1/TH2 cytokines in kidney allograft rejection. Transplant Proc 2008; 40: 3390-3392.
3. Bierer BE, Holländer G, Fruman D, et al: Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5: 763-773. (Pubitemid 23300136)
4. Tredger JM, Brown NW, Dhawan A: Immunosuppression in pediatric solid organ transplantation: opportunities, risks, and management. Pediatr Transplant 2006; 10: 879-892. (Pubitemid 44687413)
5. Shou Z, Yamada K, Inazu T, et al: Genomic structure and analysis of transcriptional regulation of the mouse zinc-fingers and homeoboxes 1 (ZHX1) gene. Gene 2003; 302: 83-94. (Pubitemid 36078400)
6. Yamada K, Kawata H, Shou Z, et al: Insulin induces the expression of the SHARP-2/Stra13/DEC1 gene via a phosphoinositide 3- kinase pathway. J Biol Chem 2003; 278: 30719-30724. (Pubitemid 36994578)
7. Kawata H, Yamada K, Matsuura K, et al: Insulin regulates the expression of the enhancer of split- and hairy-related protein-2 gene via different pathways in 3T3-L1 adipocytes and L6 myotubes. Horm Metab Res 2004; 36: 526-530. (Pubitemid 39233523)
8. Yamada K, Kawata H, Mizutani T, et al: Gene expression of basic helix-loop-helix transcription factor, SHARP-2, is regulated by gonadotropins in the rat ovary and MA-10 cells. Biol Reprod 2004; 70: 76-82. (Pubitemid 38063553)
9. Hirano S, Yamada K, Kawata H, et al: The rat enhancer of split- and hairy-related protein-2 gene: hepatic expression, genomic structure, and promoter analysis. Arch Biochem Biophys 2004; 422: 81-90. (Pubitemid 38064313)
10. Sun H, Lu B, Li RQ, et al: Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat Immunol 2001; 2: 1040-1047. (Pubitemid 33069499)
11. Applied Biosystems: Ambion®: siRNA Target Finder. Austin: Applied Biosystems/Ambion® (available at http://www.ambion.com/techlib/misc/siRNA- finder.html).
12. Geraerts M, Willems S, Baekelandt V, et al: Comparison of lentiviral vector titration methods. BMC Biotechnol 2006; 6: 34. (Pubitemid 44203871)
13. Zhou X, Cui Y, Huang X, et al: Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 2003; 14: 1089-1105. (Pubitemid 36851400)
14. Duncker SC, Wang L, Hols P, et al: The Dalanine content of lipoteichoic acid is crucial for Lactobacillus plantarum-mediated protection from visceral pain perception in a rat colorectal distension model. Neurogastroenterol Motil 2008; 20: 843-850. (Pubitemid 351814385)
15. ΔΔCT method. Methods 2001; 25: 402-408.
16. Worgall S: A realistic chance for gene therapy in the near future. Pediatr Nephrol 2005; 20: 118-124. (Pubitemid 40174021)
17. Blömer U, Naldini L, Kafri T, et al: Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649. (Pubitemid 27355322)
18. Rubinson DA, Dillon CP, Kwiatkowski AV, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406. (Pubitemid 36278858)
19. Naldini L, Blömer U, Gallay P, et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
20. Wang Q, Liu Q-Y, Liu Z-S, et al: Lentivirus mediated shRNA interference targeting MAT2B induces growth-inhibition and apoptosis in hepatocelluar carcinoma. World J Gastroenterol 2008; 14: 4633-4642.
21. Dull T, Zufferey R, Kelly M, et al: A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471. (Pubitemid 28471781)
22. Manilla P, Rebello T, Afable C, et al: Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 2005; 16: 17-25. (Pubitemid 40250328)
23. Bank A, Dorazio R, Leboulch P: A phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann NY Acad Sci 2005; 1054: 308-316. (Pubitemid 43031038)